LCM
Lynx1 Capital Management Portfolio holdings
AUM
$346M
This Quarter Return
+71.02%
1 Year Return
-2.97%
3 Year Return
+1,498.67%
5 Year Return
–
10 Year Return
–
AUM
$254M
AUM Growth
+$254M
(+68%)
Cap. Flow
+$37.9M
Cap. Flow
% of AUM
14.9%
Top 10 Holdings %
Top 10 Hldgs %
97.12%
Holding
18
New
–
Increased
9
Reduced
1
Closed
3
Top Buys
| 1 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$26.9M |
| 2 |
C4 Therapeutics
CCCC
|
$12M |
| 3 |
Stoke Therapeutics
STOK
|
$6.56M |
| 4 |
GH Research
GHRS
|
$4.27M |
| 5 |
AUTL
Autolus Therapeutics
AUTL
|
$3.19M |
Top Sells
| 1 |
CBAY
Cymabay Therapeutics
CBAY
|
$14.8M |
| 2 |
Merus
MRUS
|
$413K |
| 3 |
Zura Bio
ZURA
|
$65.5K |
| 4 |
DBVT
DBV Technologies
DBVT
|
$24.8K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALPN
1
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $72.7M | 28.58% | 3,813,926 +1,409,312 | +59% | +$26.9M |
|
2
Cabaletta Bio
CABA
$133M
| $47.9M | 18.84% | 2,110,401 +4,401 | +0.2% | +$99.9K |
|
|
3
Merus
MRUS
$4.98B
| $31.2M | 12.28% | 1,135,225 -15,000 | -1% | -$413K |
|
4
TScan Therapeutics
TCRX
$102M
| $30.5M | 11.98% | 5,224,600 | – | – |
|
|
5
C4 Therapeutics
CCCC
$185M
| $17.7M | 6.96% | 3,134,396 +2,115,166 | +208% | +$12M |
|
|
6
Stoke Therapeutics
STOK
$1.08B
| $15.6M | 6.12% | 2,956,918 +1,246,764 | +73% | +$6.56M |
|
|
AUTL
7
Autolus Therapeutics
AUTL
$399M
| $12M | 4.71% | 1,858,409 +495,384 | +36% | +$3.19M |
|
|
8
GH Research
GHRS
$837M
| $10.7M | 4.19% | 1,838,617 +735,439 | +67% | +$4.27M |
|
|
KNTE
9
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $4.73M | 1.86% | 1,997,006 | – | – |
|
|
SLN
10
Silence Therapeutics
SLN
$227M
| $4.1M | 1.61% | 235,787 | – | – |
|
|
THRX
11
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $2.84M | 1.12% | 702,415 | – | – |
|
|
PVLA
12
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $1.78M | 0.7% | 9,775,849 | – | – |
|
|
NEUP
13
Neuphoria Therapeutics Inc. Common Stock
NEUP
$21.3M
| $1.22M | 0.48% | 824,305 +8,793 | +1% | +$13K |
|
14
Nektar Therapeutics
NKTR
$568M
| $1.09M | 0.43% | 1,929,198 +162,383 | +9% | +$91.7K |
|
15
Passage Bio
PASG
$22.7M
| $383K | 0.15% | 379,159 +189,035 | +99% | +$191K |
|
|
DBVT
16
DBV Technologies
DBVT
$264M
| – | – | -18,265 | Closed | -$24.8K |
|
|
17
Zura Bio
ZURA
$133M
| – | – | -9,917 | Closed | -$65.5K |
|
|
CBAY
18
DELISTED
Cymabay Therapeutics
CBAY
| – | – | -994,161 | Closed | -$14.8M |
|